Arrowhead Reaffirms Cardiometabolic Pipeline; REDEMPLO Commercialization and sHTG Data Remain Key

What happened

Arrowhead Pharmaceuticals discussed its cardiometabolic pipeline, including the REDEMPLO launch and severe hypertriglyceridemia (sHTG) program, in a recent transcript. The DeepValue report rates the stock WAIT at $63.82, emphasizing that valuation hinges on disclosed REDEMPLO net sales and Q3 2026 sHTG Phase 3 topline data. While management reiterated commitment to these timelines, the company has yet to report product revenue, and collaboration accounting still dominates. The obesity candidates (ARO-INHBE, ARO-ALK7) add optionality but remain early. Until tangible net sales or sHTG data emerge, the risk/reward is balanced with a trim above $85 and attractive entry at $55.

Implication

Investors should require disclosed REDEMPLO net sales by the next quarterly filing and adhere to the Q3 2026 sHTG data timeline. Any slip in either erodes the premium. The obesity pipeline offers long-term optionality but does not justify current valuation absent commercial proof. Entry at $55 or below provides a margin of safety.

Thesis delta

No material change; the transcript reinforces existing guidance. The thesis remains dependent on near-term commercialization execution and sHTG catalyst adherence. The WAIT rating is maintained with conviction 3.5/5.